Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim World Congress, June 16 – 19 in Nice, France.
(All times are local; all events take place in the Nice Acropolis Convention Center unless otherwise indicated.)
Sessions related to Boston Scientific's landmark MADIT-CRT heart failure trial:
MADIT-CRT is the world's largest randomized study of New York Heart Association (NYHA) Class I and II patients(1), with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine. Boston Scientific currently has an application under review with the U.S. Food and Drug Administration (FDA) for the expansion of its CRT-D indication to include high-risk(2) NYHA Class I and II patients with Left Bundle Branch Block.
- Results of MADIT-CRT Trial: Data on QRS Duration, Gender and Echo. Arthur Moss, M.D., Principal Investigator of the MADIT-CRT trial, will present results on June 16, 9:00 – 9:30 a.m. during Session 12 in Room 3.2.
- CRT-D Effectiveness by QRS Duration and Morphology in MADIT-CRT Patients. Dr. Moss will present results on June 16, 2:45 - 3:00 p.m. during Session 46 in Room 1.2.
- MADIT-CRT: Who are the Super Responders to Cardiac Resynchronization Therapy? Dr. Moss will present results on June 16, 5:00 - 5:15 p.m. during Session 64 in Room 2.6.
- Boston Scientific Symposium: From Mirowski to MADIT-CRT: 30 years - Is Today's Technology Fulfilling Needs of Indicated Patients? Dr. Moss and Philippe Mabo, M.D., will chair a discussion on device therapy, clinical trials and physician practice on June 17, 11:00 a.m. - 12:30 p.m. during Session 112 in Room 3.2.
- Predictors of Outcome to Preventive Cardiac Resynchronization Therapy in MADIT-CRT. Dr. Moss will present results on June 18, 2:00 - 2:15 p.m. during Session 205 in Room 1.1.
- MADIT-CRT: Cardiac Resynchronization Therapy Reduces All-Cause Mortality in Females. Results will be featured on June 18, 2:00 - 5:30 p.m. during Session 216/P in the Poster Area on Level 3.
Sessions related to Boston Scientific's ALTITUDE clinical science program:
The ALTITUDE clinical science program analyzes comprehensive data from the Company's LATITUDE® Patient Management system. The ALTITUDE program enhances understanding of device therapy, outcomes and disease progression. The LATITUDE system allows physicians to conduct remote follow-up of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled visits and send data directly to physicians.
- Tachycardia Detection Programming and Shock Incidence in the ALTITUDE Study. F. Roosevelt Gilliam, M.D., will present results on June 17, 10:15 - 10:30 a.m. during Session 86 in Room 1.2.
- Noise and Oversensing-Related Inappropriate ICD Shocks Diagnosed with Remote Monitoring: The ALTITUDE EGM Study. Samuel Asirvatham, M.D., will present results on June 17, 10:00 - 10:15 a.m. during Session 86 in Room 1.2.
Other activities and sessions of interest:
- Boston Scientific Symposium: Applications and Uses of Different Ablation Catheter Tips. Serge Boveda, M.D., and Jose Guerra, M.D., will chair a discussion on ablation clinical experience on June 16, 2:00 - 3:30 p.m. during Session 47 in Room 1.3.
- The Jacques Mugica Conference. Kenneth Stein, M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group will co-chair the Jacques Mugica Conference on June 18, 4:00 - 5:30 p.m. during Session 235 in Room 3.5. Dr. Stein is also a featured speaker during this session and will deliver a presentation titled "A Multi-Sensor Approach to the Early Identification of Heart Failure Decompensation: Building a Better Mousetrap."
Boston Scientific will present its latest cardiac rhythm management and electrophysiology products at booths #D16 and D8.
New models improve heart disease risk prediction, especially for women